Corrigendum to "The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions" [Thromb. Res. 212 (2022) 72-80].

Autor: Karel MFA; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands., Tullemans BME; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands., D'Italia G; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands., Lemmens TP; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands., Claushuis TAM; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Kuijpers MJE; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; Thrombosis Expertise Centre, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, the Netherlands., Cosemans JMEM; Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands. Electronic address: judith.cosemans@maastrichtuniversity.nl.
Jazyk: angličtina
Zdroj: Thrombosis research [Thromb Res] 2022 May; Vol. 213, pp. 113. Date of Electronic Publication: 2022 Mar 22.
DOI: 10.1016/j.thromres.2022.03.012
Databáze: MEDLINE
Externí odkaz: